Krystal Biotech, Inc. Free Cash Flow 2016–2025
Krystal Biotech, Inc. reported $188.91M of free cash flow for fiscal 2025. That was 58.5% higher than fiscal 2024. Compared with fiscal 2020, the change was +561.6%.
| Fiscal year | Free Cash Flow | Change (YoY) |
|---|---|---|
| FY 2025 | $188.91M | +58.5% |
| FY 2024 | $119.18M | +218.5% |
| FY 2023 | $-100.60M | +34.5% |
| FY 2022 | $-153.55M | -32.1% |
| FY 2021 | $-116.27M | -184.1% |
| FY 2020 | $-40.93M | -63.1% |
| FY 2019 | $-25.09M | -114.8% |
| FY 2018 | $-11.68M | -184.9% |
| FY 2017 | $-4.10M | -209.2% |
| FY 2016 | $-1.33M | — |
Source: Krystal Biotech, Inc. SEC filings — cash flow statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open KRYS 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Krystal Biotech, Inc. reported $188.91M of free cash flow for fiscal 2025. That was 58.5% higher than fiscal 2024. Compared with fiscal 2020, the change was +561.6%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Krystal Biotech, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeKrystal Biotech, Inc. — frequently asked questions
What is Krystal Biotech, Inc.'s free cash flow?
Krystal Biotech, Inc. (KRYS) reported free cash flow of $188.91M for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Krystal Biotech, Inc.'s official SEC filings (cash flow statement (10-K)), refreshed nightly. Not investment advice.